Cardiovascular Properties of the Kallikrein-Kinin System

Reference

• Nolly HL, Brotis J. Kinin-forming enzyme in rat cardiac tissue. Am J Physiol 1981;265:H1209–H1214
   Google Scholar
• Sharma JN, Uma K. Cardiac kallikrein in hypertensive and diabetic rats with and without diabetes. Immunopharmacol 1996;33:341–3
   PubMedGoogle Scholar
• Sharma JN, Uma K, Yusof APM. Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. Int J Cardiol 1998;63:229–35
   PubMed Web of Science ®Google Scholar
• Sharma JN, Uma K, Yusof APM. Altered cardiac tissue and plasma kininogen levels in hypertensive and diabetic rats. Immunopharmacol 1999;34:129–32
   Google Scholar
• Oza NB, Goud HD. Kiniogeses of the aortic wall in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992;20(Suppl 9):1–3
   PubMedGoogle Scholar
• Nolly HL, Carretero OA, Sclicli AJ. Kallikrein release by vascular tissue. Am J Physiol 1993;265:H1209–H1214
   PubMed Web of Science ®Google Scholar
• Vegh A, Szekeres L, Parratt RJ. Local intracoronary infusions of bradykinin profoundly reduce the severity of ischaemia-induced arrhythmia in anaesthetized dogs. Br J Pharmacol 1991;104:294–5
   PubMed Web of Science ®Google Scholar
• Linz W, Wiemer G, Scholkens BA. Bradykinins prevent left ventricular hypertrophy in rats. J Hypertens 1993;11(Suppl 5):S96–S97
   Google Scholar
• Vegh A, Rapp JG, Parratt JR. Attenuation of the antiar-rhythmic effects of ischaemia preconditioning by blocking of bradykinin B2 receptors. Br J Pharmacol 1994;107: 1167–72
   Google Scholar
• Walls TM, Sheehy R, Hartman JC. Role of bradykinin in myocardial preconditioning. J Pharmacol Expl Ther 1994;270:681–9
   PubMed Web of Science ®Google Scholar
• Linz W, Wiemer G, Scholkens BA Contribution of bradykinin to the cardiovascular effects of ramipril. J Cardivasc Pharmacol 22 (Suppl 9):S1–S8
   Google Scholar
• Sharma JN. Kinin-forming system in the genesis of hyper-tension. Agents Actions 1984;14:200–05
   PubMedGoogle Scholar
• Sharma JN. Interrelationship between the kallikrein-kinin system and hypertension: a review. Gen Pharmacol 1988;19:177–87
   PubMedGoogle Scholar
• Sharma JN. Contribution of kinin system to the antihypertensive action of angiotensin converting enzyme inhibitors. Adv Expl Med Biol 1989;247A:197–205
   PubMedGoogle Scholar
• Sharma JN, Uma K, Noor AR, Rahman AR. Blood pressure regulation by the kallikrein-kinin system. Gen Pharmacol 1996;27:55–63
   PubMedGoogle Scholar
• Sharma JN. Does kinin mediate the hypotensive action of angiotensin converting enzyme (ACE) inhibitors? Gen Pharmacol 1990;21:451–7
   PubMedGoogle Scholar
• Sharma JN. Involvement of the kinin-forming system in physiopathology of rheumatoid inflammation. Agents Actions 1992;38(III):343–61
   Google Scholar
• Nagayasa T, Nagasawa S. Studies of human kininogen. Isolation, characterization, and cleavage by plasma kallikrein of high molecular weight (HMW) kininogen. J Biochem 1979;85:249–58
   PubMed Web of Science ®Google Scholar
• Muller-Esterl W, Iwanaga S, Nakanishi S. Kininogens revisited. TIBS 1986;11:336–9
   Web of Science ®Google Scholar
• Greenbaum LM. T-kinin and T-kininogen, children of technology. Biochem Pharmacol 33:2943–4
   PubMed Web of Science ®Google Scholar
• Okamoto H, Greenbaum LM. Pharmacological properties of T-kinin. Biochem Pharmacol 1983;32:2637–2638
   PubMed Web of Science ®Google Scholar
• Nustad K, Vaaje K, Pierce JV. Synthesis of kallikrein by rat kidney slices. Br J Pharmacol 1975;53:229–34
   PubMed Web of Science ®Google Scholar
• Sharma JN, Zeitlin IJ, Deodhar SD, Buchanan WW. Detection of tissue kallikrein-like activity in inflamed synovial tissue. Arch Int Pharmacol Ther 1983;262:279–86
   PubMedGoogle Scholar
• Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinin, kallikrein, kininogen and kininases. Pharmacol Rev 1992;44:1–80
   PubMed Web of Science ®Google Scholar
• Takada Y, Skidgel RA, Erdos, EG. Purification of human urinary prokallikrein: identification of the site of activation by the metalloproteinase thermolysin. Biochem J 1985;232:851–6
   PubMed Web of Science ®Google Scholar
• Weiss AS, Gallin JL, Kaplan AP. Fletcher factor deficiency: a diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity and kinin generation. J Clin Invest 1974;53:622–33
   PubMed Web of Science ®Google Scholar
• Cochrane CG, Revak SD, Wuepper D. Activation of Hageman factor in solid and fluid phase. A critical role of kallikrein. J Expl Med 1973;138:1564–83
   PubMed Web of Science ®Google Scholar
• Griffin JH, Cochrane CG. Mechanism for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor. Proc Natl Acad Sci 1976;73,2554–8
   PubMed Web of Science ®Google Scholar
• Mandle R, Colman RW, Kaplan A: Identification of prekallikrein and HMW-kininogen as a complex in human plasma. Proc Natl Acad Sci 1976;73:4176–83
   Google Scholar
• Thompson RE, Mandle R, Kaplan AP. Association of factor XI and high molecular weight kininogen in human plasma. J Clin Invest 1977;60:1376–80
   PubMed Web of Science ®Google Scholar
• Silverberg M, Diehl S. The autoactivation of factor XII (Hageman factor) induced by low-heparin and dextran sulfate. Biochem J 1987;248:715–20
   PubMed Web of Science ®Google Scholar
• Woolly-Miller C, Chao J, Chao L. Restriction fragment length polymorphisms mapped in spontaneously hypertensive rats using kallikrein probes. J Hypertension 1989;7:865–71
   PubMed Web of Science ®Google Scholar
• Pravenc M, Ken V, Kunes J, Sclicli G, Carretero OA, Simonet L, Kurtz TW. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 1991;17:242–6
   PubMed Web of Science ®Google Scholar
• Erdos EG. Some old and some new ideas on kinin metabolism. J Cardiovasc Pharmacol 1990;15(Suppl 6):S20–S24
   PubMedGoogle Scholar
• Marceau F, Hess JF, Bachvarov DR. The Bl receptors for kinin. Pharmacol Rev 1998;50:357–86
   PubMed Web of Science ®Google Scholar
• Regoli D. Neurohumoral regulation of precapillary vessels: the kallikrein-kinin system. J Cardiovasc Pharmacol 1984;6(Suppl 3):S401–S412
   PubMedGoogle Scholar
• D’Orleans-Juste P, de Nussi G, Vane JR. Kinins act on Bl or B2 receptors to release conjointly endothelium-derived relaxing factor and prostacyclin from bovine aortic endothelial cells. Br J Pharmacol 1989;96: 920–26
   PubMed Web of Science ®Google Scholar
• Tiffany CW, Burch, M. Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. FEBS Lett. 1989;247: 189–92
   PubMed Web of Science ®Google Scholar
• Whalley ET, Clegg S, Stewart JM, Vavrek RJ. The effect of kinin agonists and antagonists on the pain response of human blister base. Naunyn-Schmiedeberg’s Arch Pharmacol 1987;336:652–5
   Google Scholar
• Sharma JN, Yusof APM. Pro-inflammatory properties of the kallikrein-kinin system: potential for new drug therapy. Inflammopharmacol 1998;6:289–96
   PubMedGoogle Scholar
• Sharma JN, Yusof APM, Wirth KJ. The kinin antagonist Hoe 140 reduces acute paw oedema in rats caused by carrageenan, bradykinin and kaolin. Inflammopharmacol 1988;6: 9–17
   Google Scholar
• Jin LS, Seeds E, Page C, Schachter M. Inhibition of bradykinin-induced bronchocontriction in guinea-pig by a synthetic B2 receptor antagonist. Br J Pharmacol 1989;97:598–602
   PubMed Web of Science ®Google Scholar
• Sharma JN, Stewart JM, Mohsin SSJ, Katori M, Vavrek R. Influence of a kinin antagonist on acute hypotensive responses induced by bradykinin and captopril in spontaneously hypertensive rats. Agents Actions 1992;38(III):258–69
   PubMedGoogle Scholar
• Abbas SA, Sharma JN, Yusof APM. Effect of bradykinin and its antagonist on survival time after coronary artery occlusion in rats. Gen Pharmacol 1999;33:243–7
   PubMedGoogle Scholar
• Abbas SA, Sharma JN, Yusof APM. The effect of bradykinin and its antagonist on survival time after coronary artery occlusion in hypertensive rats. Immunopharmacol 1999;44:93–8
   PubMedGoogle Scholar
• Barabe J, Droulin JN, Regoli D, Park WK. Receptors for bradykinin in intestine and uterine smooth muscle. Can J Physiol Pharmacol 1977;96:920–26
   Google Scholar
• Farmer SG, Burch RM, Meeker SA, Wilkins DE. Evidence for a pulmonary B3 bradykinin receptor. Molec Pharmacol 1989;36:1–8
   PubMed Web of Science ®Google Scholar
• Saha JK, Sengupta JN, Goyal RK. Effect of bradykinin on opossum longitudinal smooth muscle: evidence for novel bradykinin receptors. J Pharmacol Expl Ther 1990;252:1012–20
   PubMed Web of Science ®Google Scholar
• Saha JK, Sengupta JN, Goyal RK. Effect of bradykinin and bradykinin analogs on the opossum lower esophageal sphincter: characterization of an inhibitory bradykinin receptor. J Pharmacol Expl Ther 1991;259:265–73
   PubMed Web of Science ®Google Scholar
• Regoli D, Barabe J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980;32:1–46
   PubMed Web of Science ®Google Scholar
• Varvrek R, Stewart JM. Competitive antagonists of bradykinin. Peptides 1985;6:161–4
   Web of Science ®Google Scholar
• Wirth KJ, Hock FJ, Albus U, Linz W, Alphermann HG, Anagnostopoulos H, Scholkens BA. Hoe 140 a new potent and long acting bradykinin antagonist – in vitro studies. Br J Pharmacol 1991;102: 774–7
   PubMed Web of Science ®Google Scholar
• Cheronis JC, Whally ET, Nguyen KT. A new class of bradykinin antagonist: synthesis and in vitro activity of bissuccinimidoalkane peptide dimers. J Med Chem 1992;35: 1563–72
   PubMed Web of Science ®Google Scholar
• Hanson L, McCullough RG, Selig WM. In vivo pharmacological profile of a novel, potent, stable BK antagonist at B1 and B2 receptors. Immunopharmacol 1996;33: 191–3
   PubMedGoogle Scholar
• Burgess GM, Perkins MN, Rang PR, Cambell EA, Brown MC, McIntyre P, Urban L, Dziadulewicz EK, Ritchie TJ, Hallett A, Snell CR, Wrigglesworth R, Lee W, Davis C, Phagoo SB, Davis AJ, Phillips EP, Darke GS, Hughes GA, Dusten A, Bloomfield GC. Bradyzide, a potent non-peptide B2 bradykinin receptor antagonist with long-lasting oral activity in animal models of inflammatory hyperalgesia. Br J Pharmacol 2000;129: 77–86
   PubMed Web of Science ®Google Scholar
• Farmer SG, Burch RM. Biochemical and molecular pharmacology of kinin receptors. Ann Rev Pharmacol Toxicol 1992;32:511–36
   PubMed Web of Science ®Google Scholar
• Burch RM. Kinin signal transduction: role of phosphoinositides and eicosanoids. J Cardiovasc Pharmacol 1990;15(Suppl 6):S44–S46
   PubMedGoogle Scholar
• Sharma JN, Zeitlin IJ. Indomethacin in low concentrations potentiates the action of some spasmogens on the isolated oestrous rat uterus. J Pharmcol 1977;29:316–7
   PubMed Web of Science ®Google Scholar
• Akbar A, Sharma JN, Yusof APM, Gan EK. Potentiation of bradykinin-induced responses in the intact and denuded epithelium of guinea pig tracheal preparations. Tissue Reactions 1998;XX:95–100
   Google Scholar
• Ransom RW, Young GS, Schneck K, Goodman CB. Characterization of solubilized bradykinin B2 receptors from smooth muscle and mucosa of guinea-pig ileum. Biochem Pharmacol 1992;43:1823–7
   PubMed Web of Science ®Google Scholar
• Schini VB, Boulanger C, Regoli D, Vanhoutte PM. Bradykinin stimulates the production of cyclic GMP via activation of B2 receptors in cultured porcine aortic endothelial cells. J Pharmacol Expl Ther 1990;252:581–85
   PubMed Web of Science ®Google Scholar
• Adetuyibi A, Mills IH. Relationship between urinary kallikrein and renal function, hypertension, and excretion of sodium and water in man. Lancet 1972;2:203–07
   PubMed Web of Science ®Google Scholar
• Defreitas FM, Farraco EZ, de Azevedo DF. General circulatory alterations induced by intravenous infusion of synthetic bradykinin in man. Circulation 1964;29:66–70
   PubMed Web of Science ®Google Scholar
• Webster ME, Gilmore JP. Influence of kallidin-10 on renal function. Am J Physiol 1964;206:714–8
   PubMed Web of Science ®Google Scholar
• McGiff JC, Itskovitz HD, Terrango NA. The action of bradykinin and eledoicin in the canine isolated kidney: relationship to prostaglandins. Clin Sci Molec Med 1975;49:125–31
   PubMedGoogle Scholar
• Margolius HS, Geller R, Pisano JJ, Sjoerdsma A. Altered urinary kallikrein excretion in human hypertension. Lancet 1971;2:1063–5
   PubMed Web of Science ®Google Scholar
• Margolius HS, Geller R, deJong W, Pisano JJ, Sjoerdsma A. Altered urinary kallikrein excretion in rats with hypertension. Circ Res 1972;30:358–62
   PubMed Web of Science ®Google Scholar
• Sharma JN, Zeithlin IJ. Altered plasma kininogen in clinical hypertension. Lancet 1981;1:125–6
   Google Scholar
• Sharma JN. Kinin system and prostaglandins in the intestine. Pharmacol Toxicol 1988;63:310–16
   PubMedGoogle Scholar
• Almeida FA, Stella RCR, Voos A, Ajzen H, Riberio AB. Malignant hypertension: a syndrome associated with low plasma kininogen and kinin potentiating factor. Hypertension 1981;3:46–50
   PubMed Web of Science ®Google Scholar
• James FW, Donaldson VH. Decrease exercise tolerance and hypertension in serve hereditary deficiency of plasma kininogen. Lancet 1981;1:889
   PubMed Web of Science ®Google Scholar
• Mohsin SSJ, Majima M, Katori M, Sharma JN. Important suppressive roles of the kallikrein-kinin system during the developmental stage of hypertension in spontaneously hypertensive rats. Asia Pacific J Pharmacol 1992;7:73–82
   Google Scholar
• Katori M, Majima M. Role of the renal kallikrein-kinin system in the development of hypertension. Immunopharmacol 1997;36:237–242
   PubMedGoogle Scholar
• Wang C, Chao L, Chao J. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 1994;23:236–43
   PubMed Web of Science ®Google Scholar
• Sharma JN, Amrah SS, Noor AR. Suppression of hypotensive responses of captopril and enalapril by kallikrein inhibitors aprotinin in spontaneously hypertensive rats. Pharmacology 1995;50:363–9
   PubMed Web of Science ®Google Scholar
• Chao J, Chao L. Kallikrein gene therapy in hypertension, cardiovascular and renal diseases. Gen Ther Molec Biol 1998;1:301–8
   Google Scholar
• Silberbauer K, Stanek B, Temple H. Acute hypotensive effect of captopril in man modified by prostaglandin synthesis inhibition. Br J Clin Pharmacol 1982;14:87S–93S
   PubMed Web of Science ®Google Scholar
• Antonaccio M. Angiotensin converting enzyme (ACE) inhibitors. Ann Rev Pharmacol Toxicol 1982;22:57–87
   PubMed Web of Science ®Google Scholar
• Sharma JN, Fernandez PG, Kim BK, Triggle CR. Systolic blood pressure responses to enalapril maleate (MK 421), an angiotensin converting enzyme inhibitor and hydrochlorothiazide in conscious Dahl salt-sensitive (S) and salt-resistant (R) rats. Can J Physiol Pharmacol 1984;62:241–3
   PubMedGoogle Scholar
• Edery H, Rosenthal T, Amitzur G, Rubinstein A, Stern N. The influence of SQ 20881 on the blood kinin system of renal hypertensive patients. Drug Expl Clin Res 1981;VII:749–56
   Google Scholar
• Smith C, Campbell S, Albano J. Urinary kallikrein excretion in normotensive and hypertensive pregnancies: 8 years later. Immunopharmacol 1990;44: 177–82
   Google Scholar
• Sharma JN. Therapeutic prospects of bradykinin antagonists. Gen Pharmacol 1993;24:267–74
   PubMedGoogle Scholar
• Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concern and opportunities. N Engl J Med 1997;337:1360–69
   PubMed Web of Science ®Google Scholar
• Lochner W, Parratt JR. A comparison of the effects of locally and systemically administered kinin on coronary blood flow and myocardial metabolism. Br J Pharmacol Chemother 1966;26:17–26
   PubMed Web of Science ®Google Scholar
• Linz W, Wiemer G, Gohlke P. Contribution of kinin to the cardiovascular action of converting-enzyme inhibitors. Pharmacol Rev 1995;47:25–50
   PubMed Web of Science ®Google Scholar
• Zhu P, Zugga CE, Simper D, Hornstein P, Allegrini PR, Buser PT. Bradykinin improves post-ischaemic recovery in the rat heart: role of high energy phosphates, nitric oxide and prostacyclin. Cardiovasc Res 1995;29:658–63
   PubMed Web of Science ®Google Scholar
• Madeddu P, Milia AF, Salis MB, Gaspa L, Gross W, Lippoldt A, Emanueli G. Renovascular hypertension in bradykinin B2-receptor knockout mice. Hypertension 1998;23: 305–309
   Google Scholar
• Kichuck MR, Seyedi N, Zhang X, Marboe CC, Michler RE, Addonzio LJ, Kaley G, Nasjletti A, Hintze TH. Regulation of nitric acid production in human coronary microvessels and the contribution of local kinin formation. Circulation 1996;94:44–51
   PubMed Web of Science ®Google Scholar
• Whalley ET, Solomon JA, Modafferi DM. CP-0127, a novel potent bradykinin antagonist increases survival in the rat and rabbit model of endotoxin shock. Agents Actions 1992;38(Suppl):431–438
   Google Scholar
• Koide A, Zeitlin IJ, Parratt JR. Kinin formation in ischaemic heart and aorta of anaesthetized rats. J Physiol (Lond) 1993;467:125P
   Google Scholar
• Scholkens BA. Kinins in the cardiovascular system. Immunopharmacol 1996;33:209–217
   PubMedGoogle Scholar
• Rubin LE, Levi R. Protective role of bradykinin in cardiac anaphylaxis. Circulation Res 1995;79:434–40
   Google Scholar
• Dela CR, Suffredini A, Page JD, Pixley RA, Kaufman N, Parrillo JE, Colman RW. Activation of kallikrein-kinin system after endotoxin administration to normal human volunteers. Blood 1993;81:3313–7
   PubMed Web of Science ®Google Scholar
• Nies AS, Forsyth RP, Williams HE, Melomon KL. Contribution of kinins to endotoxin volunteers. Blood 1993;81:3313–7
   PubMedGoogle Scholar
• Nies AS, Forsyth RP, Williams HE, Melomon KL. Contribution of kinins to endotoxin shock in unanesthetized Rhesus monkeys. Circ Res 1968;22:155–64
   PubMed Web of Science ®Google Scholar
• Kontos MA, Dagee JH, Shapiro W. General and circulatory effects of synthetic bradykinin in man. Circ Res 1964;14:352
   Web of Science ®Google Scholar
• Wilson DD, DeGaravilla L, Kihn W, Togo J, Bruch RM, Steranka LR. D-Arg-{Hyp3-D-Phe7}-bradykinin, a bradykinin antagonist reduces mortality in a rat model of endotoxin shock. Circ Shock 1989;27:93–101
   PubMedGoogle Scholar
• Feletou M, Lonchmpt M, Robineau P, Jamonneau I, Thurieau C, Fauchere JL, Villa P, Ghezzi P, Prost JF, Canet E. Effects of bradykinin B2 receptor antagonist S 16118 pguanidobenzoyl-[Hyp3,Thi5,D-Tic7,Oic8] bradykinin in different in vivo animal models of inflammation. J Pharmacol Expl Ther 1995;237:1078–85
   Google Scholar
• Cheng CP, Onishi K, Ohte N, Suzuki, Little WC. Functional effects of endogenous bradykinin in congestive heart failure. Am J Coll Cardiol 1998;31:1679–86
   PubMed Web of Science ®Google Scholar
• Fein AM, Bernard GR, Criner GJ. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). JAMA 1997;277: 482–7
   PubMed Web of Science ®Google Scholar
• McLean PG, Perretti M, Ahluwalia A. Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9-bradykinin-induced coronary vasodilation. Br J Pharmacol 1999;128: 275–82
   PubMed Web of Science ®Google Scholar